Mp15-12 Exosome-Derived Lncrna Mafg-As1 Predicts the Clinical Response to Pembrolizumab in Advanced Urothelial Carcinoma Patients

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP15)1 May 2024MP15-12 EXOSOME-DERIVED LNCRNA MAFG-AS1 PREDICTS THE CLINICAL RESPONSE TO PEMBROLIZUMAB IN ADVANCED UROTHELIAL CARCINOMA PATIENTS Nakanori Fujii, Hiroshi Hirata, Yukihiro Hitaka, Keita Kobayashi, Hideaki Ito, Naohito Isoyama, and Koji Shiraishi Nakanori FujiiNakanori Fujii , Hiroshi HirataHiroshi Hirata , Yukihiro HitakaYukihiro Hitaka , Keita KobayashiKeita Kobayashi , Hideaki ItoHideaki Ito , Naohito IsoyamaNaohito Isoyama , and Koji ShiraishiKoji Shiraishi View All Author Informationhttps://doi.org/10.1097/01.JU.0001009500.87761.bf.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Pembrolizumab is an important second-line therapy for advanced urothelial carcinoma (aUC). However, there are no effective biomarker to predict the efficacy. Therefore, biomarkers to predict the efficacy of aUC to pembrolizumab are urgently needed. Exosome-derived long non-coding RNA (Exo-lncRNA) have been reported to play an important role related to tumor progression and drug resistance. We explored whether Exo-lncRNA MAFG-AS1 was effective to predict the efficacy of pembrolizumab for the treatment of aUC. METHODS: The TCGA database was used to screen the expression of lncRNA MAFG-AS1 in bladder cancer and the expression of lncRNA MAFG-AS1 in UC tissues and normal urothelial tissues who pathologically confirmed UC at our institution were analyzed. We performed the functional analysis of lncRNA MAFG-AS1 by using bladder cancer cell lines. We analyzed the relationship between the expression level of Exo-lncRNA MAFG-AS1 and prognosis in 44 patients treated by pembrolizumab. RESULTS: The expression of lncRNA MAFG-AS1 was higher in UC tissues compared to normal urothelial tissues. After knocking down of lncRNA MAFG-AS1 in bladder cancer cells using siRNA, cell viability, invasion and migration ability were significantly decreased. Patients with clinical response were significantly lower Exo-lncRNA MAFG-AS1 expression compared to patients with no clinical response. We divided 44 patients to two groups based on median Exo-lncRNA MAFG-AS1 expression level. The high expression group had significantly worse progression-free survival and overall survival compared to the low expression group (Figure 1). In multivariate analysis, Exo-lncRNA MAFG-AS1 high expression was a significant risk factor related to the clinical response of pembrolizumab (Table 1). CONCLUSIONS: Exosome-derive lncRNA MAFG AS-1 may be an effective biomarker to predict the clinical efficacy of pembrolizumab in aUC patients. Currently we are investigating the precise mechanisms of Exo-lncRNA MAFG-AS1 on the progression of UC. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e234 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Nakanori Fujii More articles by this author Hiroshi Hirata More articles by this author Yukihiro Hitaka More articles by this author Keita Kobayashi More articles by this author Hideaki Ito More articles by this author Naohito Isoyama More articles by this author Koji Shiraishi More articles by this author Expand All Advertisement PDF downloadLoading ...